LloydsPharmacy launches new HPV vaccination service

On Monday 25th November, LloydsPharmacy introduced a new Human Papillomavirus (HPV) vaccination service in 13 stores, to help prevent more than 80% of cervical cancers.

The new service allows people aged between 12-45 to protect themselves against the sexually transmitted infection (STI) which is most commonly known for causing cancers and genital warts. The 13 LloydsPharmacy stores delivering the service are based in cities around the UK, situated close to universities.

Deep Patel, healthcare services manager at LloydsPharmacy said: “We are delighted to introduce our new HPV vaccination service. We want to help our customers look after their health and are constantly looking for new services and products to support them. HPV is a virus that most of us will come into contact with at some point, therefore we feel it’s important to give customers the opportunity to get vaccinated at their convenience. This is an opportunity for us to demonstrate that our pharmacists can play an even bigger role in helping their communities to better manage their health by delivering more services.”

The LloydsPharmacy HPV vaccination, which is administered by trained pharmacists, protects patients against 9 different types of the virus. It also targets more than 80% of cervical cancers and two types of virus that cause 90% of genital warts.

The NHS says that the HPV vaccine is most effective if given before an individual becomes sexually active, which is when they are likely to come into contact with the virus. However, getting the vaccine at any age will still protect patients.

Anna Ruthven, head of services at McKesson UK (parent company of LloydsPharmacy) commented: “We have a role to play in the education around prevention of conditions like HPV. The more people know, the more likely they are to seek out vaccinations. Prevention is far less costly to the NHS and more preferential to patients than cure. We hope that by making services like this more accessible in the community, more people will seek to protect themselves. The more trust we can build in the service, the more vaccinations we will be able to administer, and the cases of HPV, and more specifically cervical cancer, will continue to fall. We know that there is already increasing demand for the vaccine, particularly among young people, which is why we have chosen to introduce the service at 13 of our pharmacies located close to universities.”

HPV vaccinations are also available through MASTA (a McKesson company) at community-based clinics across the UK.